Investing in the future of injectable therapies
From advanced manufacturing technologies and next-generation closure systems to global capacity expansion, we help biopharma companies bring innovative therapies to patients with confidence.
Rethinking aseptic manufacturing with V-CRT®
V-CRT® (Vetter Cleanroom Technology) represents a significant advancement in aseptic processing. By combining key advantages of isolator and RABS technologies, V-CRT® enables automated cleanroom decontamination, enhanced contamination control, and greater operational flexibility. The technology has demonstrated exceptional performance, helping establish new benchmarks for quality and patient safety in sterile manufacturing.
Explore our V-CRT® technology
Investing in capacity, capability, and resilience
To support future customer needs, we are executing a long-term investment program of approximately €2 billion through 2035. New manufacturing facilities, expanded production capacity, and investments in infrastructure help create a resilient global network designed for long-term growth.
V-OVS® next: A new standard for Luer Lock syringe closure systems
Launching in 2027, V-OVS® next builds on more than two decades of proven market experience. Enhanced usability, innovative functionality, and greater versatility help create an improved user experience while maintaining product protection and integrity.
Explore our expertise in aseptic fill and finish
Save for later
Download our corporate brochure, sustainability report, press kit and much more.